CLAIM #11951 · Bristol-Myers Squibb Company (BMY) · 2024Q2 earnings call · Jul 26, 2024 · due Sep 30, 2024
“Given the delay in timing of anticipated expenses in Q2, we now expect a step-up in Q3.”
David Elkins · CFO
CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
we now expect a step-up in Q3
Reported
Operating expenses, excluding in-process R&D were impacted by higher deal-related spend, partially offset by savings from our efficiency initiatives
Verify independently
SEC filings for BMY ↗ · Claim quote is verbatim from the 2024Q2 earnings call.